Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 13/20 | 0.74 |
| ▸ | MAPT | P10636 | 10/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.74 |
| ▸ | TP53 | P04637 | 6/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | MITF | O75030 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | PKLR | P30613 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988605 | 0.86 | GAA (0.61) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL1966521 | 0.83 | GAA (0.66) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL6648128 | 0.82 | ADRA1B (0.71) | GAAMAPTSMN1; SMN2TP53HTT | |
| Hydrochloric Acid SCHEMBL6649662 | 0.81 | ADRA1B (0.69) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL1970288 | 0.81 | TUBB4A (0.68) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL29981081 | 0.81 | MAPT (0.77) | GAAMAPTSMN1; SMN2TP53KDM4E | |
| SCHEMBL2977993 | 0.81 | MAPT (0.77) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL2986228 | 0.80 | GAA (0.59) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL2989284 | 0.80 | GAA (0.59) | GAAMAPTSMN1; SMN2TP53HTT | |
| SCHEMBL1967097 | 0.80 | GAA (0.59) | GAAMAPTSMN1; SMN2TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | claimed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | GAA 441/4885MAPT 3104/4885SMN1; SMN2 3745/4885 |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | GAA 820/4885MAPT 218/4885SMN1; SMN2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.